The volume for IMTX increased for one day, resulting in a record-breaking daily growth of 235%
Immatics is a biotechnology company that is involved in the development of immunotherapies for cancer treatment. Recently, the company's stock experienced a significant increase in trading volume, resulting in a record-breaking daily growth of 235% of the 65-Day Volume Moving Average. As finance analytics, it is important to analyze this trend and understand the factors driving it.
The 65-Day Volume Moving Average is a technical analysis indicator that is used to measure the average trading volume of a stock over the past 65 days. When the volume for a stock exceeds this average, it is considered a signal of increased interest in the stock by investors.
The surge in trading volume for Immatics can be attributed to several factors, including positive developments in the company's pipeline and increased investor optimism in the biotech industry as a whole. Immatics has recently reported positive results from its clinical trials for its cancer immunotherapy treatments, which has generated significant interest among investors.
Moreover, the biotech industry has been gaining momentum recently, with several companies making breakthroughs in the development of new treatments and vaccines. This has attracted investor attention, resulting in increased trading activity for many biotech stocks, including Immatics.
The significant increase in trading volume for Immatics indicates that the stock is attracting a lot of attention from investors. However, it is important to note that such rapid growth is not sustainable over the long term and often leads to price corrections in the future. As such, investors should exercise caution and conduct thorough research before investing in Immatics or any other stock experiencing a similar trend.
IMTX in +2.70% Uptrend, advancing for three consecutive days on September 15, 2023
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IMTX advanced for three days, in of 214 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Aroon Indicator entered an Uptrend today. In of 192 cases where IMTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 20, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on IMTX as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for IMTX turned negative on September 13, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .
IMTX moved below its 50-day moving average on September 21, 2023 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.050) is normal, around the industry mean (22.634). P/E Ratio (16.393) is within average values for comparable stocks, (131.508). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.085). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (9.728) is also within normal values, averaging (305.056).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| JGVRX | 29.76 | 0.01 | +0.03% |
| JPMorgan Growth Advantage R5 | |||
| LSSNX | 25.06 | -0.04 | -0.16% |
| Loomis Sayles Small Cap Growth N | |||
| CAMIX | 23.11 | -0.06 | -0.26% |
| Cambiar International Equity Inv | |||
| GFVSX | 13.05 | -0.06 | -0.46% |
| Goldman Sachs Focused Value Instl | |||
| CGRYX | 33.01 | -0.21 | -0.63% |
| Invesco Comstock Select Y | |||
IMTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMTX has been loosely correlated with FATE. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if IMTX jumps, then FATE could also see price increases.
| Ticker / NAME | Correlation To IMTX | 1D Price Change % | ||
|---|---|---|---|---|
| IMTX | 100% | -1.18% | ||
| FATE - IMTX | 41% Loosely correlated | -3.65% | ||
| CYTK - IMTX | 36% Loosely correlated | -0.93% | ||
| KNSA - IMTX | 35% Loosely correlated | -2.92% | ||
| AUTL - IMTX | 31% Poorly correlated | -12.36% | ||
| SNPX - IMTX | 31% Poorly correlated | +30.17% | ||
More | ||||